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Cdc42 is a small RhoGTPase regulating multiple functions in eukaryotic cells. The 
activity of Cdc42 is significantly elevated in several tissues of aged mice, while the 
Cdc42 gain-of-activity mouse model presents with a premature aging-like pheno-
type and with decreased lifespan. These data suggest a causal connection between 
elevated activity of Cdc42, aging, and reduced lifespan. Here, we demonstrate that 
systemic	 treatment	of	aged	 (75-week-old)	 female	C57BL/6	mice	with	a	Cdc42	ac-
tivity-specific	inhibitor	(CASIN)	for	4	consecutive	days	significantly	extends	average	
and maximum lifespan. Moreover, aged CASIN-treated animals displayed a youthful 
level of the aging-associated cytokines IL-1β, IL-1α, and INFγ in serum and a signifi-
cantly younger epigenetic clock as based on DNA methylation levels in blood cells. 
Overall, our data show that systemic administration of CASIN to reduce Cdc42 activ-
ity in aged mice extends murine lifespan.
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1  | INTRODUC TION
Cdc42 is a small RhoGTPase involved in multiple and diverse func-
tions of eukaryotic cells, including actin cytoskeleton reorganization, 
cell	polarity,	and	cell	growth	(Cerione,	2004;	Etienne-Manneville	&	
Hall,	 2002).	 Cdc42	 cycles	 between	 an	 inactive,	GDP-bound	 state,	
and an active, GTP-bound state. The activity of Cdc42 and thus the 
level of Cdc42-GTP are significantly elevated in blood of elderly hu-
mans	 (Florian	et	al.,	2017)	and	 in	 several	 tissues	of	aged	C57BL/6	
animals, including heart, brain, lung, liver, bone marrow, spleen, and 
kidney	 (Wang,	Yang,	Debidda,	Witte,	&	Zheng,	2007).	The	cycling	
between the GDP-bound form and the GTP-bound form is tightly 
controlled by a number of different regulatory proteins. Cdc42 
GTPase-activating protein (Cdc42GAP; also known as p50RhoGAP 
or	 ARHGAP1)	 is	 a	 ubiquitously	 expressed	 negative	 regulator	 of	
Cdc42	 that	 catalyzes	hydrolysis	of	GTP	bound	 to	Cdc42	 (Moon	&	
Zheng,	 2003).	Genetic	 deletion	 of	Cdc42GAP	 in	mice	 (Cdc42GAP	
knock	out)	results	in	an	elevated	level	of	Cdc42-GTP	in	every	tissue.	
This constitutive increase of Cdc42 activity in young mice leads to a 
premature aging-like phenotype that affects several tissues and re-
sults	in	a	decrease	in	lifespan	(Wang	et	al.,	2007).	All	together,	these	
data raise the possibility that the increase in Cdc42 activity might be 
causatively	involved	in	regulating	lifespan	(Wang	et	al.,	2007).
We	 recently	 identified	 a	 specific	 small-molecule	 inhibitor	 of	
Cdc42 activity termed CASIN (Cdc42	 activity-specific	 inhibitor)	
(Liu	et	al.,	2019).	Modulation	of	Cdc42	activity	by	CASIN	has	been	
already applied to study the biological and pathological roles of 






(HSCs)	 to	CASIN	 that	 reduced	 the	 activity	 of	Cdc42	 in	 aged	 cells	
to the level found in young cells resulted in long-lasting youthful 
function of HSCs in vivo, likely due to epigenetic remodeling of aged 
cells upon modulation of Cdc42 activity (Florian et al., 2012, 2018; 
Grigoryan	et	al.,	2018).	Consequently,	we	hypothesized	that	maybe	
a short-term systemic reduction of Cdc42 activity in aged animals in 
vivo might be also beneficial for lifespan, as an elevated activity of 
Cdc42 upon aging is causatively linked to a shorter lifespan in mice.
To determine whether a short-term systemic CASIN treatment 




as single dose resulted initially in a concentration of about 10 µM 
in	 serum	 (data	not	 shown).	Our	previously	published	data	demon-
strated a functional rejuvenation of aged BM cells at a concentra-
tion of 5 µM of CASIN (Florian et al., 2012, 2018; Grigoryan et al., 
2018;	Liu	et	al.,	2019).	Therefore,	for	the	lifespan	study	we	settled	
on a dosage of 25 mg/kg, and mass spectrometry data from serum 
of old mice showed levels of CASIN 3 h after injection in the ex-
pected µM	range	 (Figure	1b).	 4	 days	of	 consecutive	 injections	did	
not induce acute toxicity, and as well, none of the treated mice died 
within 4 weeks after CASIN injections, rendering also chronic toxic-
ity issues unlikely. Quantification of Cdc42 activity 24 h after the last 
injection on day 5 demonstrated a reduction of Cdc42-GTP in aged 
bone	marrow	cells	to	the	level	seen	in	young	(Figure	1c),	confirming	
that CASIN is indeed reducing Cdc42 activity after a systemic in vivo 
treatment. Notably, aged mice treated with CASIN for only 4 con-
secutive days showed extension of their average and also maximum 
lifespan	(Figure	1d).	A	long-term	influence	of	a	short-term	treatment	
is consistent with our previous findings that transient changes in 
Cdc42 activity can modify epigenetic signatures in cells, conferring 
long-term functional changes (Florian et al., 2012, 2018; Grigoryan 
et	al.,	2018;	Leins	et	al.,	2018).
Interestingly,	weight	(Figure	S1c),	white	blood	cell	count	(WBC)	





ciated with a general alteration in the concentration of inflammatory 
F I G U R E  1   (a)	Cartoon	scheme	depicting	the	experimental	layout	of	the	lifespan	study.	(b)	Quantification	by	mass	spectrometry	of	
CASIN	concentration	in	serum	over	time	in	75-week-old	C57BL/6	mice	injected	with	a	i.p.	dose	of	25	mg/kg	of	CASIN	for	4	consecutive	
days every 24 h. The blood was harvested 3, 24, and 48 h after the last injection on day 4. n = 26 for the 3-h time point, 12 for the 24-h 
time	point,	and	7	for	the	48-h	time	point.	(c)	Representative	image	and	quantification	of	Western	blot/pull-down	of	Cdc42	total	and	active	
(Cdc42GTP)	in	bone	marrow	cells	from	young	(10-week-old)	and	aged	(75-week-old)	control	and	CASIN-treated	C57BL/6	mice.	n = 4 mice 
per group; *p <	0.05	vs	aged	control	according	to	one-way	ANOVA	and	Tukey's	multiple	comparisons	test.	(d)	Survival	curve	for	aged	control	




mice were bled together with the old mice at day 0, and the serum was used for the cytokine array young control sample. The number of 
experimental mice included was n =	7	for	young	control,	27	for	aged	control	day	0,	9	for	aged	control	day	7,	and	10	for	aged	CASIN	day	7.	
The serum samples were loaded simultaneously for all cytokines probed and all experimental arms. Some samples did not generate a signal 




group (n =	12	for	control	and	11	for	CASIN).	Bars	represent	mean	± SEM. *p < 0.05 according to unpaired t test analysis
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cytokines, termed inflammaging (Franceschi et al., 2000; Franceschi 
&	Campisi,	2014;	Minciullo	et	al.,	2016)	or,	more	recently,	aging-asso-
ciated	immune	remodeling	(AAIR)	(Leins	et	al.,	2018).	We	performed	
cytokine array analyses to investigate the extent to which aging-as-
sociated inflammatory cytokines in serum of aged mice were af-
fected by CASIN treatment. Data showed a marked increase in the 
concentrations of INFγ, IL-1β, and IL-1α on aging and the concentra-
tions for these cytokines were similar to concentrations in young an-
imals	upon	CASIN	treatment	of	aged	mice	(Figure	1e–g).	It	is	thus	a	
possibility that a reduction in the concentrations of these cytokines 
upon CASIN treatment might contribute to the increase in lifespan 
observed in these animals. Interestingly, IL-9 was the only cytokine 




a large number of cytokines their level in serum was not altered at all 
either	by	aging	or	CASIN	treatment	(Figure	S2).
Previously, the methylation status of CpG sites within the genes 
Prima1, Hsf4, and Kcns1	was	shown	to	qualify	as	 likely	predictor	of	
biological	age	of	C57BL/6	mice	(Han	et	al.,	2018).	Therefore,	DNA	
methylation profiling of these CpGs might serve as biological epi-
genetic	clock	(Bell	et	al.,	2019).	Applying	this	C57BL/6-trained	DNA	
methylation marker panel to blood cells from aged animals treated 
with CASIN 9 weeks after treatment, we observed that epigenetic 
age predictions did not correlate anymore to the chronological age 
as in aged control animals, but resulted in a biological age prediction 
that was on average 9 weeks younger than their chronological age 
(Figure	1i).	 These	data	 imply	 that	 epigenetic	 changes	 underlie	 the	
extended longevity of aged CASIN-treated mice, while reinforcing 
the necessity to mechanistically validate tissues, cells, and biological 
pathways involved in the extension of longevity.
Interestingly, a recent analysis of changes in the epigenome and 
transcriptome with aging across different tissues identified that the 
up-regulation of the inflammatory response and gamma interferon 
pathways correlated best with aging both across tissues and species 
(Benayoun	et	al.,	2019).	Many	age-related	diseases,	such	as	obesity,	
metabolic syndrome, diabetes, cardiovascular diseases, cancer, de-
pression, and Alzheimer's disease, share an inflammatory pathogen-
esis; moreover, the activation of inflammatory pathways appears to 
be involved in the pathophysiology of sarcopenia and frailty. Elevated 
concentrations of interferon γ, as detected in our study, might thus 
serve as a conserved hallmark of aging and might be functionally 
linked to lifespan. Similarly, both interleukin 1α and interleukin 1β 
have been associated with many aging-associated phenotypes and 
diseases	(Mantovani,	Dinarello,	Molgora,	&	Garlanda,	2019).	As	for	
IL-9, which showed an increase in the concentration in serum after 
CASIN treatment, it is a pleiotropic cytokine mainly produced by T 
helper	9	(Th9)	cells	and	exerts	documented	effects	on	lymphocytes,	
mast	 cells,	 and	 resident	 lung	cells	 (Goswami	&	Kaplan,	2011).	Our	
data further support a role for these cytokines in the regulation of 
lifespan. Moreover, our data reveal that the methylation status of 
CpG sites within the genes Prima1, Hsf4, and Kcns1 in blood cells 
strongly correlates with biological age and might thus serve as a val-
idated	biomarker	of	aging	in	C57BL/6	mice.
Multiple studies in organisms ranging from flies and worms to 
humans have demonstrated that genetics plays an important role in 
determining	lifespan	(Kuningas	et	al.,	2008),	while	there	are	robust	
and reproducible approaches to extend lifespan and healthspan by 
non-genetic means like dietary restriction (Longo et al., 2015; Mercken 
et	 al.,	 2013;	Mitchell	 et	 al.,	 2016)	 or	 pharmacological	 compounds	
(https://www.nia.nih.gov/resea rch/dab/inter venti ons-testi ng-progr 
am-itp)	 (Campisi	 et	 al.,	 2019;	 Palliyaguru,	 Moats,	 Di	 Germanio,	
Bernier,	&	de	Cabo,	2019).	Cdc42	has	been	implied	in	the	regulation	
in multiple organisms, ranging from yeast and Caenorhabditis elegans 
to	humans	(Florian	et	al.,	2017;	Kerber,	O’Brien,	&	Cawthon,	2009;	
Meitinger	et	al.,	2014;	Witten	&	Bonchev,	2007).	We	demonstrate	
here that a reduction of Cdc42 activity in aged mice indeed extends 
lifespan. Cdc42 might thus be similar to other phylogenetically con-
served	 genes	 and	 pathways	 (Fontana,	 Partridge,	 &	 Longo,	 2010;	
Kennedy	&	Lamming,	2016;	Kuningas	et	al.,	2008),	a	critical	target	in	
the context of longevity. Interestingly, to the best of our knowledge, 
inhibition of Cdc42 activity by CASIN and inhibition of mTOR by 
rapamycin are the only pharmacological treatments reported so far 
that have significant effects on murine lifespan when given already 
quite	late	in	life	(75	weeks	of	age	or	more)	and	only	temporary	(only	
4	days	 for	CASIN;	90	days	 for	 rapamycin)	 (Bitto	et	al.,	2016).	This	
argues for a mechanism of action of CASIN that is distinct from the 
other pharmacological interventions for lifespan, which usually are 
either given earlier in life and/or then provided continuously for long 
time to achieve a significant effect. Further work will be necessary 
to identify and mechanistically validate cells and pathways targeted 
by CASIN in aged mice that are causatively involved in extending 
lifespan and which are likely epigenetic in nature.
2  | E XPERIMENTAL PROCEDURES
2.1 | Mice
All	mice	included	in	the	study	were	females	C57BL/6	and	were	ob-






and mice that died due to laboratory errors were excluded. Mice 
that needed to be euthanized because they were scored as “weak 
and about to die” according to our approved animal license proto-
col for evaluating mouse health status remained part of the dataset. 
Allocation to control or treated group was done randomly (20 mice 
each	experimental	group).
Median lifespan, 95% confidence intervals, and survival analysis 
were	calculated	by	Prism	GraphPad	v7.0c.	Of	note,	the	median	lifes-
pan	of	our	control	group	matches	data	obtained	for	C57BL/6j	mice	in	
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a	 large	set	of	 lifespan	studies	of	diverse	 inbred	mouse	strains	 (Yuan	
et	al.,	2009).	Young	C57BL/6	mice	were	10-week-old	and	were	hosted	
in the same room and setting of the old mice. Animals were housed 
in groups of up to 4 animals per cage with bedding and paper nesting 
material with a temperature range of 22 ± 1°C and a relative humidity 
of 55 ± 10%. Animals had access to food (V1124-3, ssniff®)	and	water	
ad libitum. Animals were kept at a day/night rhythm of 12/12 h, a tem-
perature range of 22 ± 1°C, a relative humidity of 55 ± 10%, an air 
exchange rate of 15 times throughout the entire experiment. All mouse 
experiments were approved by the Regierungspraesidium Tuebingen, 
Baden-Württemberg,	and	the	IACUC	at	CCHMC,	USA	(protocol	num-
bers:	35/9185.81-3/1363	and	1472	and	IACUC2017-0096).
2.2 | CASIN solution and IP treatment
CASIN was prepared fresh before injection by dissolving the drug 
directly	in	beta-cyclodextrin	solution	(Sigma	#H5784).	IP	injections	
were done in the morning every 24 h for 4 consecutive days during 
week	75	of	age	of	the	mice.	Control	mice	were	injected	with	equal	




treatment. The same stock of CASIN was used for the whole study. 
CASIN was provided as lyophilized powder.
2.3 | Flow cytometry of PB
PB cell immunostaining was performed according to standard 
procedures, and samples were analyzed on a LSR II flow cytom-
eter	 (BD	Biosciences).	For	PB	lineage	analysis,	the	antibodies	used	
were all from eBioscience: anti-CD3ε	 (clone	145-2C11),	 anti-B220	
(clone	 RA3-6B2),	 anti-Mac-1	 (clone	 M1/70),	 and	 anti-Gr-1	 (clone	
RC57BL/6-8C5).	Lineage	FACS	analysis	data	are	plotted	as	the	per-
centage of B220+, CD3+, and Myeloid (Gr-1+, Mac-1+, and Gr-1+ Mac-
1+)	cells	among	total	white	blood	cells.	WBC,	RBC,	Ly,	NE,	Mo	counts	
were generated by using the hemocytometer Hemavet 950, Drew 
Scientific	Inc,	(FL	33014),	USA.
2.4 | Liquid Chromatography–Mass Spectrometry 
(LC-MS/MS) measurements of CASIN 
pharmacokinetics in mouse serum
A LC/MS/MS ion chromatography protocol was employed to meas-
ure	 serum	 CASIN	 concentration	 ranging	 0.1–10	 μM by compar-
ing serum CASIN from i.p. injected mice at varying times with the 
standard curve derived by in vitro spiking mouse serum with defined 
doses of CASIN. An autosampler maximum recovery vials with caps 
(Waters),	 an	 UPLC-MS	 system	 (Waters	 Quattro	 Premier	 XE	 mass	
spectrometry	with	ACQUITY	UPLC	system),	an	ACQUITY	BEH	C18	





2 min, to 50% solvent A at 2.1 min, to 46% solvent A over 9.9 min, 
and then, after changing to 30% at 12.1 min, to 1% solvent A over 
5.9 min, then to 60% solvent A at 18.1 min, and this was held for 
2 min. Column temperature was kept at 25°C. The capillary voltage 
is 3 KV for ES- mode, cone voltage is 45 V, collision 30 V, desolvation 
temperature, 350°C; desolvation gas flow is 600 L/h; source tem-
perature is 120°C; and MRM transition m/z is 305.1->244.
2.5 | Cytokine array. Luminex Method
Cytokine concentrations in the sample supernatants were de-
termined by using MilliplexTM Multiplex kits (MilliporeSigma, 
Darmstadt,	 Germany)	 according	 to	 the	 manufacturer's	 protocol.	
Briefly, in a 96-well black plate, 25 µl sample in duplicate was incu-
bated with 25 µl antibody-coated beads overnight at 4C on a plate 
shaker. Plates were then washed 2 times using the BioTek 405 TS 
(BioTek,	Winooski,	VT),	and	25	µl of secondary antibody was added 
and incubated at room temperature for 1 h while shaking. Finally, 
25 µl of streptavidin-RPE was added directly to the secondary an-
tibody and incubated for 30 min at room temperature with shaking. 
Plates were then washed 2 more times, and 150 µl of sheath fluid 
was added. Plates were shaken for 5 min and then read using luminex 
technology on the Milliplex Analyzer (MilliporeSigma, Darmstadt, 
Germany).	 Concentrations	 were	 calculated	 from	 standard	 curves	
using recombinant proteins and expressed in pg/ml.
2.6 | Cdc42-GTPase effector domain pull-
down assays
Relative levels of GTP-bound Cdc42 were determined by an effec-
tor pull-down assay. Briefly, lineage-depleted BM cells (106)	 were	
lysed in a Mg2+	 lysis/wash	buffer	(Upstate	Cell	Signaling	Solutions)	
containing 10% glycerol, 25 mM sodium fluoride, 1 mM sodium or-
thovanadate,	and	a	protease	inhibitor	cocktail	 (Roche	Diagnostics).	
Samples were incubated with PAK-1 binding domain/agarose beads, 
and	 bound	 (activated)	 as	 well	 as	 unbound	 (non-activated)	 Cdc42	
fractions were probed by immunoblotting with an anti-Cdc42 anti-
body	(Millipore,	rabbit	polyclonal).	Activated	protein	was	normalized	
to total protein and/or β-actin	(Sigma),	and	the	relative	amount	was	
quantified	by	densitometry.
2.7 | Analysis of the epigenetic aging signature
CASIN	 (Xcessbio	 #M60040)	 was	 prepared	 freshly	 before	 in-
jection. To this, it was dissolved in DMSO to a concentration of 
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100	mM	and	diluted	 in	cyclodextrin	solution	 (Sigma	#H5784).	 IP	
injections of 25 mg/kg were done on 4 consecutive days in the 
morning	 starting	 at	 an	 age	 of	 77–86	weeks.	 Control	 mice	 were	
injected	with	equal	volume	of	the	solvents.	Mice	were	sacrificed	
8–9	 weeks	 after	 treatment,	 and	 blood	 was	 collected	 by	 heart	
puncture. The analysis of DNA methylation levels was analyzed at 
three	age-associated	CG	dinucleotides	(CpGs)	as	described	previ-
ously	(Brown	et	al.,	2020;	Han	et	al.,	2018).	Briefly,	genomic	DNA	
was isolated from blood samples, bisulfite converted, and DNA 
methylation was analyzed within the three genes (Prima1, Hsf4, 
and Kcns1)	 by	 pyrosequencing.	 The	 DNA	methylation	 results	 at	
these sites were integrated into a multivariable model for epige-
netic age predictions in B6 mice, which clearly correlate with the 
chronological	age	(Han	et	al.,	2018).	Chronological	and	biological	
age of CASIN-treated and control mice was compared using an un-
paired t test. Since the data were not normally distributed, all data 
were potentiated to obtain normal distribution before the statisti-
cal analysis was performed.
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